FDA Allows Sale of Philip Morris Electronic Tobacco Product

FDA Allows Sale of Philip Morris Electronic Tobacco Product

An electronic tobacco device may now hit the US market after getting a green light from the US Food and Drug Administration, the agency announced Tuesday.

The agency made clear that it has not deemed the device — Philip Morris International’s IQOS “tobacco heating system” — to be safe. And its decision to permit sales is not tantamount to FDA approval.

The device is not an e-cigarette or vape like the ones that have surged in popularity among middle and high school students. Rather, it’s a noncombustible device that heats, without burning, “tobacco-filled sticks wrapped in paper to generate a nicotine-containing aerosol,” the FDA said.

The agency said the move followed “a rigorous science-based review,” after which it decided that the product may have public health merit in part because the device contains “fewer toxic chemicals than cigarette smoke, and many of the toxins identified are present at lower levels than in cigarette smoke.”

Critics have expressed concerns about such research being widely company-funded.

“Ensuring new tobacco products undergo a robust premarket evaluation by the FDA is a critical part of our mission to protect the public, particularly youth, and to reduce tobacco-related disease and death,” Mitch Zeller, director of the FDA’s Center for Tobacco Products, said in a statement Tuesday.

Moira Gilchrist, vice president of strategic and scientific communications for Philip Morris International, said the FDA’s decision was a “milestone” that would allow the company to bring its product — which is sold in other countries — to US smokers.

The company says it expects to be distributing and marketing IQOS in approximately 90 to 120 days, starting in Atlanta.
But the FDA’s decision raised eyebrows among health advocates. Some are concerned that the product could spread among kids, similar to vaping devices such as Juul.

The decision also comes less than a month after Dr. Scott Gottlieb, who took a strong stance against underage tobacco use as the agency’s commissioner, stepped down, prompting questions about how aggressively the agency would continue to pursue the issue under new leadership.

Without strict FDA oversight, “there is a serious risk that IQOS will become the next Juul and worsen the current youth epidemic,” Matthew L. Myers, president of the Campaign for Tobacco-Free Kids, said in a statement Tuesday.

He said his organization has repeatedly “raised concerns with the FDA that Philip Morris International has marketed IQOS in other countries in ways that clearly appeal to kids, including through social media, sponsorships of events like beach parties and fashion shows, and slick stores and kiosks that look like they’re selling tech gadgets, not addictive tobacco products.”

Robin Koval, president and CEO of the Truth Initiative, said in an e-mailed statement that “the introduction of another nicotine delivery device to the U.S. market while we are in the midst of a youth e-cigarette epidemic is concerning.”

Harold Wimmer, president and CEO of the American Lung Association, said in a statement that he’s “deeply concerned” about the product’s potential health impacts.

“The Lung Association urges the FDA to carefully monitor how this product is actually being used — and by whom,” Wimmer said. “FDA must take steps to protect youth from beginning a tobacco addiction with this product.”

The FDA said it will keep tabs on what happens as the device hits the market, including any uptake among youth. If this happens, it could be grounds for the agency to reverse its decision.

“We’ll be keeping a close watch on the marketplace, including how the company is marketing these products,” Zeller said. This includes complying with regulations intended to prevent kids from being exposed to the product — on websites and social media, for example.

The agency will also require that package labels and ads warn about the product’s addictiveness. And the tobacco company can’t market the devices “with claims of reduced exposure or reduced risk,” the FDA said. In order to do that, the company has a separate application in the works.

Philip Morris International has put its weight behind IQOS as more smokers have ditched traditional cigarettes, affecting sales. In the first quarter of 2019, the company had “more than 10 million IQOS users worldwide,” CCEO André Calantzopoulos previously said in a statement. In that period, the shipment volume of its so-called heated tobacco units grew 20.2%.

The company’s interest in smoke-free alternatives to cigarettes is part of a sector-wide shift. Last year, tobacco giant Altria took a 35% stake in Juul in a deal worth $12.8 billion.

Altria, which spun off Philip Morris International years ago, will now be distributing IQOS under an exclusive agreement with the company.

Recent Articles

I went home and told my girlfriend, who, after Googling the name of the business I bought it from, told me that, yes, it was technically weed. But it was CBD. She started laughing, telling me I had been ripped off.
State-sanctioned medical and recreational cannabis programs benefit the average user in many ways. Still, they remain a double-edged sword for dispensary owners, greenhouse growers, and others who earn their living from the cannabis industry. There are plenty of profits to be had, sure, but how exactly are you expected to secure your cash or process electronic transactions when banks refuse to work with you?
Aubrey Amatelli wants to help dispensaries and cannabis retailers navigate one of the toughest parts of the industry: money. When the company she worked for right out of grad school was acquired by JPMorgan, Aubrey entered the complex world of payments and has stayed there for her entire career.
There’s a paradox to business conferences. The best ones manage to swing from buttoned down to wildly unscripted—sometimes seconds apart. For attendees, it’s the combination of personal connections and professional development that makes regular trips to conferences worthwhile. And in an industry like this one, pulling that off is harder than it looks.
Your shop is not only a smoke shop; It's also a hangout spot and a community hub. It is a place where the regulars know your staff by name, and your staff knows what the regulars need. That's the secret sauce that the big-box chains can't replicate, and it starts with who you put behind the counter. A well-staffed smoke shop is an operational strategy, but it's also a community. In lean economic times, that community is what keeps the lights on. When people feel like your shop is their spot, they don't stop coming in when money's tight. They prioritize it. It all starts with Hiring.
Dr. Macias first fell in love with science while studying at Howard University, where she completed her undergraduate studies and later earned her PhD in cellular and molecular biology. While at Howard, she became especially interested in cancer research due to personal ties. Growing up in a Creole family and predominantly Black community in Louisiana, Dr. Macias watched many women around her battle breast cancer, so at Howard, she decided to focus her research on the BRCA1 gene.
It’s almost amazing that the same institutions that brought us the 2008 financial crisis have a problem with selling glass pipes. Almost. The truth is that an industry's past sins are only held against it when the money isn’t right. Big banks were willing to risk cratering the U.S. housing market because the profits were too good to ignore. But the cannabis industry rolls a different kind of paper, so instead of a slap on the wrist, it gets a surcharge.
Smokeshop and counterculture enthusiasts enjoy discovery as part of the experience. Customers enjoy browsing. When they walk into a shop, they don't simply grab a product and leave. They look for something new. This is the main reason flyers and posters still work. Smokeshops and dispensaries are highly visual environments. You want to see bold artwork, psychedelic graphics, and street-style posters that naturally capture attention.